Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: July 5, 2024

Background The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining was objective this systematic review and meta-analysis. Methods This meta-analysis performed according to PRISMA guidelines. A literature search detect randomised clinical trials that have quantified on C-reactive protein (CRP) levels compared placebo or a control group (other glucose-lowering drugs). primary outcome CRP index (final CRP/basal CRP). random-effects model used. Results Thirteen were considered eligible ( n = 26,131). Overall, therapy associated lower values (SMD −0.56; 95% CI −0.69 −0.43, I 92%) −0.45; −0.68 −0.23, 82%).Such an association similarly observed when different treatment regimens (subcutaneous vs. oral) populations (patients without T2DM) analysed. sensitivity analysis showed results robust. Conclusion present demonstrated use reduction inflammation irrespective population evaluated regimen These findings would explain events. Systematic Review Registration PROSPERO [CRD42024500551].

Language: Английский

---

Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study

Clinical Research in Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

Language: Английский

---

Alkaloids Derived from Tyrosine: Phenethylisoquinoline (Colchicine)

Springer eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 36

Published: Jan. 1, 2025

Language: Английский

---

The association between energy‐adjusted dietary inflammatory index and 10‐year cardiovascular risk: Fasa adult cohort study

Food Science & Nutrition, Journal Year: 2024, Volume and Issue: 12(8), P. 5530 - 5537

Published: May 13, 2024

Abstract A healthy diet is dominant in cardiovascular disease (CVD) prevention. Inflammation pivotal for CVD development. This study aimed to evaluate the association between pro‐inflammatory and risk. cross‐sectional involved 10,138 Fasa adult cohort participants. After excluding participants with missing data, Energy‐Adjusted Dietary Inflammatory Index (E‐DII) was calculated assess inflammatory potential of using recorded Food Frequency Questionnaire. Framingham risk score (FRS) used predict 10‐year CVD. The E‐DII high investigated multinominal regression. exclusion, mean age studied individuals ( n = 10,030) 48.6 ± 9.6 years, including 4522 men. Most were low (FRS <10%) (87.6%), while 2.7% them ≥20%). median FRS 2.80 (1.70, 6.30). ranged from −4.22 4.49 (mean 0.880 1.127). significantly associated FRS. result persisted after adjusting confounding factors both genders. revealed that increases Consequently, reducing should be considered an effective dietary intervention

Language: Английский

---

Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials

Cardiovascular Drugs and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 29, 2024

Language: Английский

---

Managing chronic coronary syndrome: how do we achieve optimal patient outcomes?

Expert Review of Cardiovascular Therapy, Journal Year: 2024, Volume and Issue: 22(6), P. 243 - 263

Published: May 18, 2024

Introduction Chronic coronary syndrome (CCS) remains the leading cause of death worldwide with high admission/re-admission rates. Medical databases were searched on CCS & its management.

Language: Английский

---

Effect on C‐reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta‐analysis

Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 296(3), P. 302 - 305

Published: July 11, 2024

Dear Editor, Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Although several therapeutic options are available to reduce LDL-cholesterol (LDL-C), many patients continue experience major (CV) events. In ASCVD, inflammation plays a critical role, contributing significantly residual CV risk [1]. Several anti-inflammatory therapies have been evaluated risk, recently, U.S. Food Drug Administration approved use low-dose colchicine myocardial infarction (MI), stroke, coronary revascularization, or death in adult with established ASCVD multiple factors [2, 3]. Meta-analyses shown that (0.5–1.0 mg) can lead reduction C-reactive protein (CRP) levels by −0.36 mg/L (95%CI, −0.51 −0.20) artery [4, 5], −0.66 −0.98 −0.35) acute MI [6], which translates into 35% 44% events, respectively. Nevertheless, some studies suggested an effect lipid-lowering therapies. recent meta-analysis involving 171,668 subjects from 53 randomized control trials (RCTs), we demonstrated serum CRP concentration statins (−0.65 [95%CI, −0.87 −0.43]), bempedoic acid (−0.43 −0.67 −0.20]), ezetimibe (−0.28 −0.48 −0.08]), was independent LDL-C changes [7]. Given growing interest targeting further inclusion among preventive [8], it appears compare on plasma levels. Therefore, sought quantify additional adding acid, ezetimibe, added background statin treatment. Because no trial directly compares impact versus therapies, performed network according PRISMA guidelines. PubMed, Web Science, EMBASE, Cochrane Library, ClinicalTrial.gov were searched inception November 2023. Inclusion criteria as follows: (1) RCTs human, parallel design, phase II, III, IV; (2) English language; (3) using interventions top treatment (defined more than 80% treated at baseline); (4) reporting levels; (5) intervention duration 3 weeks. Pooled estimates assessed both fixed-effect random-effects models within Bayesian hierarchical setting, assuming equal heterogeneity across all comparisons. When significant detected (as determined t2 I2 statistics, p < 0.05), results model presented. We individual bias (RoB) tool [9]. Sensitivity analysis excluding high RoB evaluation. All analyses conducted gemtc package R (version 4.3.2). Additional information is provided Supporting Information section. A total 22,287 30 (Table S1; median follow-up: 4.5 months) included (22 for [18,386 subjects], [2961 5 [940 subjects]). Pairwise indicated reduced −0.75 (95% CI, −0.88 −0.61) (Fig. 1a) compared alone. meta-analysis, addition showed differences direct comparison add-on (−0.22 [95% −0.69 0.30]) (−0.44 −1.05 0.23]) 1b, Figure S1). Bempedoic therapy, not different reducing −0.72 0.29]) 1b). The comparing relative (Figure S2) sensitivity removing S2, Figures S3 S4) consistent. summary, our suggests be comparable short term raises question about will benefit most. general, data suggest patient goal therefore eligible combination achieve benefits terms achieved colchicine. Notably, although has consistently associated causal nature association [10]. Furthermore, may capture aspects chronic inflammatory processes. Further research warranted explore comparative medium- long-term these drugs overall systemic inflammation. Sining Xie Manuela Casula made contributions concept design. Federica Galimberti responsible acquisition, analysis, interpretation data. Elena Olmastroni did statistical analysis. prepared draft manuscript. authors contributed revision Alberico L. Catapano supervision study. thank members META-LIPID Group who unpublished data: Hiroshi Ogawa (for HIJ-PROPER trial), JoAnne Foody, Michael Louie trials). SX, FG, EO, MC report disclosures. No funding received this project. work ALC, MC, FG supported part grant Ricerca Corrente Italian Ministry Health IRCCS MultiMedica. ALC and/or honoraria advisory boards, consultancy, speaker bureaus Amarin, Amgen, Amryt, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Medscape, Menarini, Merck, Novartis, Peer Voice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, Corpus, Ultragenyx, Viatris. confirm supporting findings study derived published articles (available main text section) authors. For information, see Table S1 List S2 Risk Bias evaluation each Network diagram treatments comparisons outcome "CRP levels" Analysis percentage Chart showing contribution low, moderate S4 Please note: publisher content functionality any supplied Any queries (other missing content) should directed corresponding author article.

Language: Английский

---

Low-dose colchicine for stroke prevention: a systematic overview of systematic reviews and meta-analyses

Journal of Stroke and Cerebrovascular Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 108167 - 108167

Published: Dec. 1, 2024

Language: Английский

---

Colchicine: Repositioning an “ancient” medicine in the 21st century

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 445 - 464

Published: Oct. 31, 2024

The main indications for colchicine treatment until recently were gout, pericarditis, familial Mediterranean fever and some other auto-inflammatory diseases. expansion of (repositioning) the use in direction prevention cardiovascular complications should be considered as one major events medicine XXI century. Deciphering role inflammation most important mechanism development atherosclerosis has created prerequisites concept anti-inflammatory therapy atherosclerosis, which low-dose can take an place, complementing effects aspirin, statins antihypertensive therapy. analysis materials from randomized placebo-controlled studies indicates a decrease frequency patients with coronary heart disease (by 31%) who have suffered myocardial infarction 23%), well 33%), stroke, need revascularization mortality. low dose (0.5 mg/day) is approved by U.S. Food Drug Administration disease. It assumed that future will place pathology associated atherosclerotic vascular

Language: Английский

---

Angelica sinensis Polysaccharide Suppresses Pyroptosis in Myocardial Ischemia/Reperfusion Injury via the FN1/NF-κB/NLRP3 Pathway

Natural Product Communications, Journal Year: 2024, Volume and Issue: 19(9)

Published: Sept. 1, 2024

Background Pyroptosis, a form of inflammatory programmed cell death, has recently emerged as pivotal factor in the pathogenesis myocardial ischemia/reperfusion (MI/R) injury. Despite its significance, effective therapeutic strategies targeting MI/R-induced pyroptosis remain elusive current clinical practice. Previous studies have demonstrated promising anti-inflammatory effects Angelica sinensis polysaccharide (ASP) context certain disorders. Objectives We aimed to investigate ASP on MI/R injury and elucidate potential molecular mechanisms by combining transcriptomic analysis with complementary vivo vitro experiments. Materials methods H9c2 cells were used establish hypoxia/reoxygenation (H/R) model, was induced rats ligating releasing left anterior coronary artery. Myocardial tissue samples harvested for sequencing bioinformatic analyses. Cardioprotective evaluated through electrocardiography, echocardiography, histological examination. Enzyme-linked immunosorbent assay (ELISA) employed quantify levels mediators. Biochemical assays conducted assess biomarkers Caspase-1 activity. Western blotting performed analyze protein expression Fibronectin 1 (FN1), Nuclear kappa B (NF-κB) p65, phosphorylated NF-κB p65 (p-NF-κB p65), Nod-like receptor 3 (NLRP3), Gasdermin-D (GSDMD). Results Pretreatment conferred potent cardioprotective rat model injury, evidenced significant attenuation infarct size, enzyme levels, ST-segment elevation alongside notable improvements cardiac function. Transcriptomic profiling unveiled that differentially expressed genes modulated treatment predominantly implicated pyroptosis-elicited response. Concordantly, both experiments substantiated effectively attenuated pyroptosis, manifested diminished pyroptosis-related indicators, encompassing proportion TUNEL-positive cells, activation, GSDMD cleavage, liberation pro-inflammatory cytokines. Further mechanistic investigations revealed inhibition FN1/NF-κB/NLRP3 signaling pathway. Conclusions Our investigation, leveraging system-level profiling, demonstrates confers against suppression cardiomyocyte culminating from downregulation

Language: Английский

---